Cancer Treatment Reviews
Volume 31, Issue 3 , Pages 236-241, May 2005

Adding irinotecan to first-line gemcitabine improves tumour response in advanced pancreatic cancer:☆☆☆☆☆☆

Abstracted from: Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumour response rate. J Clin Oncol 2004;22:3776–83.

  • Desmond Yip, MBBS, FRACP

      Affiliations

    • Medical Oncology Unit, The Canberra Hospital and Australian National University Medical School, Canberra, Australia
    • Corresponding Author InformationCorresponding author. Tel.: +61 262 442 220; fax: +61 262 444 266
    • ,
  • David Goldstein, MBBS, FRACP

      Affiliations

    • Prince of Wales Hospital and University of New South Wales, Sydney, Australia

published online 09 May 2005.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Sources of funding: Supported by a grant from Pfizer Corp. New York, NY, USA.

☆☆ For correspondence: Caio Max Sao Pedro Rocha Lima, MD, University of Miami and Sylvester Cance Center, 1475 NW 12th Avenue, Suite 3310, Miami, FL 33162, USA. E-mail: croche@med.miami.edu.

☆☆☆ Abstract provided by Bazian Ltd., London.

PII: S0305-7372(05)00053-8

doi:10.1016/j.ctrv.2005.03.003

Cancer Treatment Reviews
Volume 31, Issue 3 , Pages 236-241, May 2005

Article Tools